BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 27043680)

  • 1. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
    El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
    Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
    Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of adrenocortical carcinoma.
    Ranvier GG; Inabnet WB
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term complete remission of metastatic adrenocortical carcinoma.
    Cárdenas-Salas J; Castelo B; Regojo RM; González-Sanchez JA; Álvarez-Escolá C
    Horm Mol Biol Clin Investig; 2023 Mar; 44(1):67-71. PubMed ID: 36069780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
    World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
    Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
    Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
    J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
    Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
    Seki M; Nomura K; Hirohara D; Kanazawa M; Sawada T; Takasaki K; Demura H
    Endocr Relat Cancer; 1999 Dec; 6(4):529-33. PubMed ID: 10730906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
    Veytsman I; Nieman L; Fojo T
    J Clin Oncol; 2009 Sep; 27(27):4619-29. PubMed ID: 19667279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
    Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Demeure MJ; Somberg LB
    Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
    Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
    Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.